Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desensitization for drug allergy.

Mariana Castells1

  • 1Harvard Medical School, Boston, Massachusetts, USA. mcastells@partners.org

Current Opinion in Allergy and Clinical Immunology
|November 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiratory Viruses, Self-Diagnosis, Early Treatment and Prophylaxis.

Viruses·2026
Same author

Anaphylaxis and Epinephrine Use in Pregnancy.

The journal of allergy and clinical immunology. In practice·2026
Same author

Localization of mast cells in human brain tissue: Implications for neuropsychiatric symptoms in COVID-19.

Journal of neuropathology and experimental neurology·2026
Same author

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

The Journal of allergy and clinical immunology·2026
Same author

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.

The World Allergy Organization journal·2026
Same author

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal of the American Academy of Dermatology·2026
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Rapid drug desensitization safely induces temporary tolerance to allergens like antibiotics and aspirin. This enables essential treatments for patients with severe infections or cardiac conditions, improving outcomes.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Drug allergy desensitization induces temporary clinical unresponsiveness to drug antigens.
  • Gradual reintroduction of drug antigens allows full therapeutic doses, preventing anaphylaxis.

Purpose of the Study:

  • Review indications and outcomes of recent antibiotic and aspirin desensitization protocols.
  • Highlight the role of rapid desensitization in specific clinical scenarios.

Main Methods:

  • Review of recent literature on drug desensitization protocols.
  • Analysis of outcomes for antibiotic and aspirin desensitization.

Main Results:

  • Rapid desensitization protocols are effective for Type I mast cell/IgE-dependent reactions (e.g., penicillin anaphylaxis).

Related Experiment Videos

  • Anaphylactoid reactions to aspirin, vancomycin, and taxenes also respond to rapid desensitization.
  • Cellular mechanisms involving syk and STAT6 are implicated but not fully understood.

    • Conclusions:

    • Successful rapid desensitization enables critical treatments for infected and cardiac patients.
    • Standardized protocols with high success rates should be adopted as standard care.